(Q34326518)

1 August 2017

1 reference

title

Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma (English)

1 reference

1 August 2017

Fassas A

1

1 reference

PubMed ID

11486311

1 August 2017

Tricot G

series ordinal

2

1 reference

1 August 2017

1 July 2001

1 reference

1 August 2017

Seminars in Hematology

1 reference

1 August 2017

38

1 reference

1 August 2017

231-242

1 reference

1 August 2017

3

1 reference

Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

The treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Highly purified CD34-positive cells reconstitute hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

High frequency of graft-versus-host-like syndromes following syngeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Monoclonal proteins and renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Intensive treatment for multiple myeloma: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

High-dose busulfan in patients with myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Repeat administration of high dose melphalan in relapsed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Autologous stem cell transplantation for relapsed and primary refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Cytomegalovirus colitis after autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Multiple myeloma treated with high dose intravenous melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Infectious complications after CD34-selected autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Purification and characterization of mouse hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990015-0

7 January 2021

10.1016/S0037-1963(01)90015-0

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11486311